HealthUnlockedHealthUnlocked
AboutLog in

Experiences with

Arzerra

  • Posts

  • Communities

19 public posts

Important SARS-CoV-2 and Covid-19 information for Chronic Lymphocytic Leukaemia/CLL patients

In addition, they may experience: • Treatment-related immunodeficiency (such as that resulting from anti-CD20 monoclonal antibody treatment such as Rituximab (Mabthera/Rituxan), Obinutuzumab (Gazyva) or ofatumumab (Arzerra) In a recent study, ‘individual risk factors associated with a poor prognosis
In addition, they may experience: • Treatment-related immunodeficiency (such as that resulting from anti-CD20 monoclonal antibody treatment such as Rituximab (Mabthera/Rituxan), Obinutuzumab (Gazyva) or ofatumumab (Arzerra) In a recent study, ‘individual risk factors associated with a poor prognosis
CLLerinOz profile image
CLLerinOz
Volunteerin CLL Support

Duvelisib Dosing Modification Does Not Compromise Efficacy in Heavily Pretreated CLL/SLL

Furthermore, treatment with the PI3K inhibitor led to a superior median progression-free survival (PFS) compared with ofatumumab (Arzerra) while producing rapid and durable responses in heavily pretreated patients.
Furthermore, treatment with the PI3K inhibitor led to a superior median progression-free survival (PFS) compared with ofatumumab (Arzerra) while producing rapid and durable responses in heavily pretreated patients.
Jm954 profile image
Jm954
Administratorin CLL Support

Arzerra for Marginal Zone B Cell Lymphoma

She is now trying Arzerra. Wondering if anyone has had Arzerra as a treatment for this as what I read shows it as a treatment for CLL.
She is now trying Arzerra. Wondering if anyone has had Arzerra as a treatment for this as what I read shows it as a treatment for CLL.
Hidden profile image
Hidden
in Non Hodgkin's Lymphoma Friends
Want to take advantage of all our features? Just log in!
or

Supporting my grandmother

Just wondered if anyone else had had Arzerra for lymphoma rather than CLL.
Just wondered if anyone else had had Arzerra for lymphoma rather than CLL.
Hidden profile image
Hidden
in CLL Support

FDA Approves Duvelisib for CLL and Follicular Lymphoma - Sep 24, 2018

In DUO, duvelisib reduced the risk of disease progression or death by 60% versus ofatumumab (Arzerra) in patients with relapsed/refractory CLL/SLL who had received at least 2 prior lines of therapy.
In DUO, duvelisib reduced the risk of disease progression or death by 60% versus ofatumumab (Arzerra) in patients with relapsed/refractory CLL/SLL who had received at least 2 prior lines of therapy.
lankisterguy profile image
lankisterguy
Volunteerin CLL Support

Verastem, with Phase 3 Results, to Request FDA Approve Oral Duvelisib to Treat Advanced CLL and SLL

This was 3.4 months longer than in patients treated with Arzerra. Source: http://phx.corporate-ir.net/phoenix.zhtml?c=250749&p=irol-newsArticle&ID=2298616
This was 3.4 months longer than in patients treated with Arzerra. Source: http://phx.corporate-ir.net/phoenix.zhtml?c=250749&p=irol-newsArticle&ID=2298616
wmay13241 profile image
wmay13241
in CLL Support

Duvelisib Drug Succeeds in Late-Stage Trial

Here is a paragraph from the writeup: "Verastem's drug, Duvelisib, showed a superior progression-free survival rate than the current standard of care, Novartis's Arzerra (ofatumumab), when tested on patients suffering from cancers that affect cells of the immune system, Verastem said."
Here is a paragraph from the writeup: "Verastem's drug, Duvelisib, showed a superior progression-free survival rate than the current standard of care, Novartis's Arzerra (ofatumumab), when tested on patients suffering from cancers that affect cells of the immune system, Verastem said."
crystalsky profile image
crystalsky
in CLL Support

Dr Susan O'Brien Sheds Light on Role of Next-Generation Agents in CLL

[/i] OncLive interview with Dr O'Brien: http://global.onclive.com/web-exclusives/expert-sheds-light-on-role-of-nextgeneration-agents-in-cll Drugs mentioned: ibrutinib (Imbruvica) idelalisib (Zydelig) duvelisib in trial versus ofatumumab (Arzerra) TGR-1202 (PI3K inhibitor) acalabrutinib, (ACP-196) a
[/i] OncLive interview with Dr O'Brien: http://global.onclive.com/web-exclusives/expert-sheds-light-on-role-of-nextgeneration-agents-in-cll Drugs mentioned: ibrutinib (Imbruvica) idelalisib (Zydelig) duvelisib in trial versus ofatumumab (Arzerra) TGR-1202 (PI3K inhibitor) acalabrutinib, (ACP-196) a
AussieNeil profile image
AussieNeil
Administratorin CLL Support

Biologic or Immune Therapies for CLL

These include rituximab (Rituxan), ofatuzumab (Arzerra), and obinituzumab (Gazyva). Among other topics, I discuss the difference between type I and type II monoclonal antibodies.
These include rituximab (Rituxan), ofatuzumab (Arzerra), and obinituzumab (Gazyva). Among other topics, I discuss the difference between type I and type II monoclonal antibodies.
bkoffman profile image
bkoffman
CLL CURE Heroin CLL Support

UK - NICE Guidance for NHS use of Ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia -

Two buses arrive at the same time on the same day making new treatments available to NHS England & Wales CLL patients Technology appraisal guidance [TA344] Published date: June 2015 You can access full guidance details on the NICE website here: http://www.nice.org.uk/guidance/ta344 [i]Ofatumumab (Arzerra
Two buses arrive at the same time on the same day making new treatments available to NHS England & Wales CLL patients Technology appraisal guidance [TA344] Published date: June 2015 You can access full guidance details on the NICE website here: http://www.nice.org.uk/guidance/ta344 [i]Ofatumumab (Arzerra
HAIRBEAR_UK profile image
HAIRBEAR_UK
Administratorin CLL Support

Arzerra (ofatumumab) PBS listed in Australia

[/i] http://www.pharmacydaily.com.au/news/arzerra-pbs-listed/41548 This news even made the National 7 News, which gave a good overview of CLL and included a brief interview with Dr Con Tam. Neil
[/i] http://www.pharmacydaily.com.au/news/arzerra-pbs-listed/41548 This news even made the National 7 News, which gave a good overview of CLL and included a brief interview with Dr Con Tam. Neil
AussieNeil profile image
AussieNeil
Administratorin CLL Support

Ofatumumab (Arzerra®) is accepted for restricted use within NHS Scotland.

Ofatumumab (Arzerra) [i]Advice following a full submission assessed under the orphan process ofatumumab (Arzerra®) is accepted for restricted use within NHS Scotland.
Ofatumumab (Arzerra) [i]Advice following a full submission assessed under the orphan process ofatumumab (Arzerra®) is accepted for restricted use within NHS Scotland.
HAIRBEAR_UK profile image
HAIRBEAR_UK
Administratorin CLL Support

My husband is on Arzerra (Ofatumumab) for CLL and he has had 2 treatments. Any suggestions on lethargy and weakness as side effects?

judithpetersen profile image
judithpetersen
in CLL Support

Marketing authorisation application submitted to the European Medicines Agency for the use of ofatumumab for first line treatment

GlaxoSmithKline plc and Genmab A/S have submitted a variation to the marketing authorisation application (MAA) to the European Medicines Agency (EMA) for the use of Arzerra (ofatumumab) in combination with an alkylator-based therapy, to be used for treatment of Chronic Lymphocytic Leukaemia (CLL) patients
GlaxoSmithKline plc and Genmab A/S have submitted a variation to the marketing authorisation application (MAA) to the European Medicines Agency (EMA) for the use of Arzerra (ofatumumab) in combination with an alkylator-based therapy, to be used for treatment of Chronic Lymphocytic Leukaemia (CLL) patients
AussieNeil profile image
AussieNeil
Administratorin CLL Support

Update on Novel B-Cell Receptor Signaling Inhibitors from NCCN 8th Annual Congress on Hematologic Malignancies

Brief mention is also made of the benefits observed when using Ibrutinib with Ofatumumab (Arzerra) and rituximab.
Brief mention is also made of the benefits observed when using Ibrutinib with Ofatumumab (Arzerra) and rituximab.
AussieNeil profile image
AussieNeil
Administratorin CLL Support

Arzerra(R) (Ofatumumab) granted FDA 'Breakthrough Therapy Designation' for Previously Untreated CLL

Source http://www.gsk.com/media/press-releases/2013/fda-grants-gsk-and-genmabs-arzerra---ofatumumab--breakthrough-th.html
Source http://www.gsk.com/media/press-releases/2013/fda-grants-gsk-and-genmabs-arzerra---ofatumumab--breakthrough-th.html
Cllcanada profile image
Cllcanada
Top Poster CURE Heroin CLL Support

CLL - a Cancer of the Immune System

temperature should be treated seriously, particularly if you are having treatment or have been treated with a CD20 monoclonal antibody such as Rituximab/Rituxan/Mabthera, Obinutuzumab/Gazyva or Ofatumumab/Arzerra within the last year, where you may be experiencing Late Onset Neutropenia https://healthunlocked.com
temperature should be treated seriously, particularly if you are having treatment or have been treated with a CD20 monoclonal antibody such as Rituximab/Rituxan/Mabthera, Obinutuzumab/Gazyva or Ofatumumab/Arzerra within the last year, where you may be experiencing Late Onset Neutropenia https://healthunlocked.com
AussieNeil profile image
AussieNeil
Administratorin CLL Support

Genmab Announces Top-Line Phase II Results for Ofatumumab Combined with Bendamustine in Untreated and Relapsed CLL

ReleaseID=760980 Note: ARZERRA is not approved for the treatment of untreated CLL anywhere in the world. It is approved for use in fludarabine refractory CLL, in the US and EU
ReleaseID=760980 Note: ARZERRA is not approved for the treatment of untreated CLL anywhere in the world. It is approved for use in fludarabine refractory CLL, in the US and EU
Cllcanada profile image
Cllcanada
Top Poster CURE Heroin CLL Support

Arzerra (ofatumumab) approved in Japan for CLL

"We are pleased that patients in Japan will now have access to Arzerra. Japan is another important market for Arzerra and commercialization continues on track," said Jan van de Winkel, Ph.D. Chief Executive Officer of Genmab.
"We are pleased that patients in Japan will now have access to Arzerra. Japan is another important market for Arzerra and commercialization continues on track," said Jan van de Winkel, Ph.D. Chief Executive Officer of Genmab.
Cllcanada profile image
Cllcanada
Top Poster CURE Heroin CLL Support
    Filter results
    Posted in
    Sort by
    HealthUnlocked
    © 2022 All rights reserved.

    Company

    About Us

    Our Team

    Partner with us

    Careers

    Product

    Health terms A to Z

    Communities A to Z

    Start a Community

    Support

    Help Centre

    Community Guidelines

    Contact us

    Cookies settings